Related Experiment Video
Updated: May 2, 2026
09:06
Growth Assays to Assess Polyglutamine Toxicity in Yeast
Published on: March 5, 2012
13.1K
Therapeutic opportunities in polyglutamine disease
1Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA. rehughes@u.washington.edu
Nature Medicine
|April 3, 2001
Summary
Polyglutamine diseases are inherited neurodegenerative disorders. Research is advancing understanding of their molecular causes and identifying drug targets for new treatments.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Polyglutamine diseases are a group of inherited neurodegenerative disorders.
- These conditions result from expanded polyglutamine (PolyQ) protein tracts.
- Understanding PolyQ pathology is crucial for developing effective therapies.
Purpose of the Study:
- To review the molecular mechanisms underlying PolyQ diseases.
- To identify potential therapeutic targets for PolyQ disorders.
- To discuss rational drug discovery approaches for these conditions.
Main Methods:
- Literature review of molecular mechanisms in PolyQ diseases.
- Analysis of current research on PolyQ pathology.
- Synthesis of information on potential drug targets.
Main Results:
- Significant progress has been made in understanding PolyQ disease mechanisms.
- Several molecular targets for therapeutic intervention have been identified.
- Advances facilitate rational, target-based drug discovery.
Conclusions:
- Continued research into PolyQ pathology is essential.
- Target-based drug discovery offers a promising strategy for PolyQ diseases.
- Rational approaches can accelerate the development of treatments for these disorders.
Related Concept Videos
01:22Lysosomal Hydrolases
3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
01:31Translation
16.8K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
Translation Produces the Building Blocks of Life
Proteins are...
16.8K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121